Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, LLC, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics. In addition, Invetx announced the appointments of Bill Brondyk, PhD, as chief scientific officer and Colin Giles, PhD, as chief development officer to its executive team.

Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians.